Scholar Rock to Present at Upcoming Healthcare Conferences
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company, announced its participation in two upcoming virtual investor conferences. The Jefferies Virtual London Healthcare Conference is scheduled for November 19, 2020, at 1:45 pm ET, with a live webcast available on the company's website. Additionally, Scholar Rock will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. The company focuses on discovering innovative treatments targeting protein growth factors for serious diseases.
- None.
- None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming virtual investor conferences:
-
Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 1:45 pm ET.
- A live webcast of this presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.
- Piper Sandler 32nd Annual Virtual Healthcare Conference being held November 30- December 3, 2020.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
